CA2331266A1 - Les exons 4 et 7 codent pour des domaines distincts de transactivation et de localisation de la chromotine dans le facteur esx - Google Patents

Les exons 4 et 7 codent pour des domaines distincts de transactivation et de localisation de la chromotine dans le facteur esx Download PDF

Info

Publication number
CA2331266A1
CA2331266A1 CA002331266A CA2331266A CA2331266A1 CA 2331266 A1 CA2331266 A1 CA 2331266A1 CA 002331266 A CA002331266 A CA 002331266A CA 2331266 A CA2331266 A CA 2331266A CA 2331266 A1 CA2331266 A1 CA 2331266A1
Authority
CA
Canada
Prior art keywords
esx
exon
polypeptide
nucleic acid
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002331266A
Other languages
English (en)
Inventor
Christopher C. Benz
Gary K. Scott
Chuan-Hsiung Chang
Yesu Chao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2331266A1 publication Critical patent/CA2331266A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Mathematical Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne deux domaines de ESX (à restriction épithéliale par une séquence de sérine), un membre de la famille des régulateurs de transcription ETS, qui constituent des cibles particulièrement efficaces utiles dans le criblage des modulateurs ESX. L'un des domaines, l'éxon 4 de ESX est un transactiveur efficace et peut être utilisé dans des constructions permettant de réguler positivement ou négativement des gènes ou des ADNc, et en particulier des gènes ou des ADNc sous le contrôle d'un promoteur contenant un élément ETS. L'autre domaine, l'éxon 7, est capable d'acétylation et le niveau d'acétylation pouvant être utilisé dans des analyses recherchant une régulation anormale dans ESX.
CA002331266A 1998-06-16 1999-06-15 Les exons 4 et 7 codent pour des domaines distincts de transactivation et de localisation de la chromotine dans le facteur esx Abandoned CA2331266A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8940998P 1998-06-16 1998-06-16
US60/089,409 1998-06-16
US28953599A 1999-04-09 1999-04-09
US09/289,535 1999-04-09
PCT/US1999/013277 WO1999065929A1 (fr) 1998-06-16 1999-06-15 Les exons 4 et 7 codent pour des domaines distincts de transactivation et de localisation de la chromotine dans le facteur esx

Publications (1)

Publication Number Publication Date
CA2331266A1 true CA2331266A1 (fr) 1999-12-23

Family

ID=26780560

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002331266A Abandoned CA2331266A1 (fr) 1998-06-16 1999-06-15 Les exons 4 et 7 codent pour des domaines distincts de transactivation et de localisation de la chromotine dans le facteur esx

Country Status (4)

Country Link
EP (1) EP1087985A1 (fr)
AU (1) AU4563599A (fr)
CA (1) CA2331266A1 (fr)
WO (1) WO1999065929A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165783A4 (fr) * 1999-03-26 2002-09-11 Human Genome Sciences Inc 47 proteines humaines secretees
EP1366072A2 (fr) * 2000-11-02 2003-12-03 Myocontract Ag Promoteur specifique de compose relie au facteur de transcription ets, et transactivateurs associes
AU2002337831A1 (en) * 2001-10-12 2003-05-06 Beth Israel Deaconess Medical Center, Inc. Methods of diagnosis of autoimmune disease
DE06814528T1 (de) 2005-09-12 2012-01-05 The Regent Of The University Of Michigan Wiederkehrende genfusionen bei prostatakrebs
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2171094B1 (fr) 2007-07-06 2011-11-16 The Regents of the University of Michigan Réarrangements de gènes mipol1 -etv1
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
JP5800817B2 (ja) 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US9341639B2 (en) 2013-07-26 2016-05-17 Industrial Technology Research Institute Apparatus for microfluid detection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789200A (en) * 1996-10-31 1998-08-04 Smithkline Beecham Corporation Human ETS family member, ELF3

Also Published As

Publication number Publication date
AU4563599A (en) 2000-01-05
EP1087985A1 (fr) 2001-04-04
WO1999065929A1 (fr) 1999-12-23

Similar Documents

Publication Publication Date Title
US7125969B1 (en) ETS-related gene overexpressed in human breast and epithelial cancers
ES2321954T3 (es) Composiciones y procedimientos para el diagnostico de tumores.
KR100331363B1 (ko) 사이클린복합체재배열및그것과관련된용도
WO1998023782A9 (fr) Nouveau gene lie a la famille ets, surexprime dans les cancers humains du sein et de l'epithelium
ES2331657T3 (es) Metodos para el diagnostico de tumores.
EP0905236A1 (fr) Facteur de Transcription DP-1
US20030028905A1 (en) Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
EP1246917B1 (fr) Polypeptides humains stra6
CA2331266A1 (fr) Les exons 4 et 7 codent pour des domaines distincts de transactivation et de localisation de la chromotine dans le facteur esx
USRE43497E1 (en) Anti-MIF antibodies
US6448020B1 (en) Molecules associated with the human suppressor of fused gene
US20060199781A1 (en) Assays based on BTF3 activity
US6869766B2 (en) Gene associated with regulation of adiposity and insulin response
US7910704B2 (en) Human p53 splice variant displaying differential transcriptional activity
ES2248458T3 (es) Polipeptido secretado y acidos nucleicos que lo codifican.
WO1997043414A2 (fr) Gene suppresseur du carcinome basocellulaire
ES2259058T3 (es) Gen amplificado en tumores, y materiales y procedimientos relacionados.
WO1999032609A1 (fr) Molecules associees au gene fusionne humain
ES2261559T3 (es) Polipeptidos secretados y transmenbrana asi como los acidos nucleicos que los codifican.
US7160677B1 (en) Transcription factor DP-1
EP0964925A2 (fr) x

Legal Events

Date Code Title Description
FZDE Discontinued